TerminatedPhase 3NCT01749306
A Study of the Efficacy and Safety of ABH001 in the Treatment of Patients With Epidermolysis Bullosa Who Have Wounds That Are Not Healing
Studying Inherited epidermolysis bullosa
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Shire Regenerative Medicine, Inc.
- Principal Investigator
- Alan Arbuckle, MD, FAAD, FAAPH&E Enterprises
- Intervention
- ABH001(biological)
- Enrollment
- 1 target
- Eligibility
- All sexes
- Timeline
- 2012 – 2013
Study locations (14)
- Phoenix Children's Hospital, Phoenix, Arizona, United States
- Lucile Packard Children's Hospital at Stanford University, Redwood City, California, United States
- Rady Children's Hospital - San Diego/UCSD, Pediatric and Adolescent Dermatology, San Diego, California, United States
- Denver Children's Hospital, Aurora, Colorado, United States
- Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, Illinois, United States
- Virginia Clinical Research, Inc, Norfolk, Virginia, United States
- Landeskrankenhaus Salzburg-Universitätsklinikum der Paracelsus Medizinischen Privatuniversität, Salzburg, Salzburg, Austria
- Toronto Regional Wound Healing Clinic, Mississauga, Ontario, Canada
- University of Montreal, Montreal, Quebec, Canada
- Hôpital Necker-Enfants Malades, Paris, Île-de-France Region, France
- University of Freiburg (Studiensekretariat Hautklinik Universitätsklinikum Freiburg - Hautklinik), Freiburg im Breisgau, Baden-Wurttemberg, Germany
- Warszawki Uniwersytet Medyczny Katedra I Klinika Dermatologiczna, Warsaw, Masovian Voivodeship, Poland
- Hospital CUF Descobertas, Lisbon, Lisbon District, Portugal
- Hospital Universitario La Paz, Madrid, Madrid, Spain
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT01749306 on ClinicalTrials.govOther trials for Inherited epidermolysis bullosa
Additional recruiting or active studies for the same condition.
- ACTIVE NOT RECRUITINGPHASE3NCT05838092Allogeneic ABCB5-positive Dermal Mesenchymal Stromal Cells for Treatment of Epidermolysis Bullosa (Phase III)RHEACELL GmbH & Co. KG
- ACTIVE NOT RECRUITINGPHASE3NCT05464381Allogeneic ABCB5-positive Dermal Mesenchymal Stromal Cells for Treatment of Epidermolysis Bullosa (Phase III, Cross-over)RHEACELL GmbH & Co. KG
- ACTIVE NOT RECRUITINGNANCT05248503Impact of Complex Care Training of Hereditary Epidermolysis Bullosa on Caregiver Burden (FIREB)Assistance Publique - Hôpitaux de Paris
- RECRUITINGNANCT05954416FARD (RaDiCo Cohort) (RaDiCo-FARD)Institut National de la Santé Et de la Recherche Médicale, France